Clinical Trial Update: AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion status of a Phase 2 study evaluating AZD2171 (cediranib) in patients with relapsed or refractory B-cell chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• AZD2171 (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED